Mineralys Therapeutics, Inc. (MLYS) Tops Q2 EPS by 40c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq futures slip on chip weakness; S&P 500 holds gains
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
- Goldman says this FX trade is the best hedge for the AI drawdown
Tweet
Share
E-mailGet Alerts MLYS Hot Sheet
Join SI Premium – FREE
Mineralys Therapeutics, Inc. (NASDAQ: MLYS) reported Q2 EPS of ($0.66), $0.40 better than the analyst estimate of ($1.06).
For earnings history and earnings-related data on Mineralys Therapeutics, Inc. (MLYS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Icahn Enterprises L.P. (INGR) Tops Q3 EPS by 12c ; Offers Guidance
- Insight Enterprises (NSIT) Tops Q3 EPS by 73c ; Offers Guidance
- Entrada Therapeutics, Inc. (TRDA) Tops Q3 EPS by 7c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
